Hemostemix (CVE:HEM) Shares Up 11.1% – Still a Buy?

Shares of Hemostemix Inc. (CVE:HEM) traded up 11.1% during mid-day trading on Tuesday . The company traded as high as C$0.15 and last traded at C$0.15. 111,000 shares traded hands during trading, a decline of 74% from the average session volume of 429,920 shares. The stock had previously closed at C$0.14.

Hemostemix Trading Up 7.4%

The business’s fifty day moving average is C$0.11 and its two-hundred day moving average is C$0.14. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The firm has a market cap of C$21.13 million, a price-to-earnings ratio of -4.23 and a beta of 0.20.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.